[go: up one dir, main page]

SV2018005613A - Agentes, usos y metodos para el tratamiento - Google Patents

Agentes, usos y metodos para el tratamiento

Info

Publication number
SV2018005613A
SV2018005613A SV2018005613A SV2018005613A SV2018005613A SV 2018005613 A SV2018005613 A SV 2018005613A SV 2018005613 A SV2018005613 A SV 2018005613A SV 2018005613 A SV2018005613 A SV 2018005613A SV 2018005613 A SV2018005613 A SV 2018005613A
Authority
SV
El Salvador
Prior art keywords
treatment
antibodies
agents
methods
frontotemporary
Prior art date
Application number
SV2018005613A
Other languages
English (en)
Inventor
Rønn Lars Christian Biilmann
Ibrahim John Malik
Jeffrey B Stavenhagen
Søren Christensen
Arnout Gerritsen
De Brink Edward Van
Paul Parren
Jong Rob De
Jan Egebjerg
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of SV2018005613A publication Critical patent/SV2018005613A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A ANTICUERPOS MONOCLONALES ANTI-SORTILINA QUE SE HA ENCONTRADO QUE SON ÚTILES EN LA CORRECCIÓN DE UN NILA PRESENTE INVENCIÓN SE REFIERE A ANTICUERPOS MONOCLONALES ANTI-SORTILINA QUE SE HA ENCONTRADO QUE SON ÚTILES EN LA CORRECCIÓN DE UN NIVEL DEFICIENTE DE PROGRANULINA (PGRN). EN PARTICULAR, PUEDEN USARSE ESTOS ANTICUERPOS EN EL TRATAMIENTO DE DEMENCIA FRONTOTEMPORAL (DFT) Y ESCLEROSIS LATERAL AMIOTRÓFICA (ELA).VEL DEFICIENTE DE PROGRANULINA (PGRN). EN PARTICULAR, PUEDEN USARSE ESTOS ANTICUERPOS EN EL TRATAMIENTO DE DEMENCIA FRONTOTEMPORAL (DFT) Y ESCLEROSIS LATERAL AMIOTRÓFICA (ELA).
SV2018005613A 2015-07-13 2018-01-11 Agentes, usos y metodos para el tratamiento SV2018005613A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1512215.3A GB201512215D0 (en) 2015-07-13 2015-07-13 Agents,uses and methods

Publications (1)

Publication Number Publication Date
SV2018005613A true SV2018005613A (es) 2018-02-23

Family

ID=54013862

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2018005613A SV2018005613A (es) 2015-07-13 2018-01-11 Agentes, usos y metodos para el tratamiento

Country Status (35)

Country Link
US (6) US10479835B2 (es)
EP (1) EP3322726B1 (es)
JP (2) JP6979397B2 (es)
KR (1) KR102778576B1 (es)
CN (3) CN114478774A (es)
AR (1) AR105335A1 (es)
AU (1) AU2016292980B2 (es)
BR (1) BR112018000771A2 (es)
CA (1) CA2989739A1 (es)
CL (2) CL2018000092A1 (es)
CO (1) CO2017012988A2 (es)
CR (1) CR20180002A (es)
DO (1) DOP2018000014A (es)
EA (1) EA201890038A1 (es)
EC (1) ECSP18002725A (es)
ES (1) ES3024469T3 (es)
GB (1) GB201512215D0 (es)
HR (1) HRP20250602T1 (es)
HU (1) HUE071424T2 (es)
IL (1) IL256503B (es)
JO (1) JO3710B1 (es)
MA (1) MA42440B1 (es)
MX (1) MX2018000506A (es)
NI (1) NI201800007A (es)
PE (1) PE20181014A1 (es)
PH (1) PH12018500100A1 (es)
PL (1) PL3322726T3 (es)
RS (1) RS66856B1 (es)
RU (1) RU2735639C2 (es)
SV (1) SV2018005613A (es)
TN (1) TN2017000534A1 (es)
TW (1) TWI760305B (es)
UA (1) UA125136C2 (es)
WO (1) WO2017009327A1 (es)
ZA (1) ZA201708613B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3280441T (lt) 2015-04-07 2021-11-25 Alector Llc Anti-sortilino antikūnai ir jų naudojimo būdai
WO2016164608A1 (en) 2015-04-07 2016-10-13 Alector Llc Methods of screening for sortilin binding antagonists
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
EP4212210A1 (en) 2018-07-13 2023-07-19 Alector LLC Anti-sortilin antibodies and methods of use thereof
EP3666281A1 (en) * 2018-12-14 2020-06-17 Insusense ApS Compositions comprising sortilin-1
PH12022551598A1 (en) * 2019-12-23 2023-11-20 Denali Therapeutics Inc Progranulin variants
EP4171743A4 (en) 2020-06-24 2024-07-24 Prothena Biosciences Limited Antibodies recognizing sortilin
JP2025530891A (ja) 2022-06-23 2025-09-18 ドラウプニル バイオ エーピーエス リソソーム内の細胞外標的の分解を選択的に誘導する二機能性分子
CN118496354A (zh) * 2023-02-15 2024-08-16 三优生物医药(上海)有限公司 包含共同轻链的抗体库、其制备方法及其用途
WO2025031098A1 (zh) * 2023-08-09 2025-02-13 瑞诺元(苏州)生物科技有限公司 一种分拣蛋白1特异性的纳米抗体、含有其的重组aav及应用
WO2025132764A1 (en) * 2023-12-21 2025-06-26 Amylonix Ab A sortilin-binding polypeptide

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU650629B2 (en) 1989-08-09 1994-06-30 Rhomed Incorporated Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5101990A (en) 1990-03-23 1992-04-07 Continental Pet Technologies, Inc. Stretch blow molded oblong or oval container
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
WO1993001227A1 (en) 1991-07-08 1993-01-21 University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
ES2146648T3 (es) 1993-03-09 2000-08-16 Genzyme Corp Procedimiento de aislamiento de proteinas de la leche.
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
DK1150918T3 (da) 1999-02-03 2004-12-20 Biosante Pharmaceuticals Inc Fremgangsmåde til fremstilling af terapeutiske calciumphosphatpartikler
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
EP1210372B1 (en) 1999-07-29 2008-01-23 Medarex, Inc. Human monoclonal antibodies to her2/neu
KR20020047132A (ko) 1999-08-24 2002-06-21 메다렉스, 인코포레이티드 인간 씨티엘에이-4 항체 및 그의 용도
ES2295228T3 (es) 2000-11-30 2008-04-16 Medarex, Inc. Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos.
US6881557B2 (en) 2001-07-12 2005-04-19 Arrowsmith Technologies Llp Super humanized antibodies
WO2004056385A2 (en) 2002-12-20 2004-07-08 Neuronicon Aps Modulation of activity of neurotrophins
EA016609B1 (ru) 2005-11-28 2012-06-29 Генмаб А/С Рекомбинантные моновалентные антитела и способы их получения
WO2008076262A2 (en) 2006-12-15 2008-06-26 Merck & Co., Inc. Receptor for amyloid beta and uses thereof
EP3225251B1 (en) 2006-12-21 2020-02-12 H. Lundbeck A/S Modulation of activity of proneurotrophins
WO2009097006A2 (en) 2007-08-10 2009-08-06 Medarex, Inc. Hco32 and hco27 and related examples
US8377701B2 (en) 2008-04-27 2013-02-19 H. Lundbeck A/S Specific ligands to sortilin
WO2009154995A2 (en) 2008-05-27 2009-12-23 Kyowa Hakko Kirin Co., Ltd. Interleukin 10 receptor (il-10r) antibodies and methods of use
US20120039865A1 (en) 2008-08-19 2012-02-16 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
WO2010069331A2 (en) 2008-12-19 2010-06-24 H. Lundbeck A/S Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders
RU2536232C2 (ru) * 2011-07-01 2014-12-20 Олег Ильич Эпштейн Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
WO2014071131A1 (en) 2012-11-02 2014-05-08 The Brigham And Women's Hospital, Inc. Sortilin 1 is a novel inducer of vascular calcification
LT3280441T (lt) 2015-04-07 2021-11-25 Alector Llc Anti-sortilino antikūnai ir jų naudojimo būdai
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
EP4212210A1 (en) 2018-07-13 2023-07-19 Alector LLC Anti-sortilin antibodies and methods of use thereof

Also Published As

Publication number Publication date
CA2989739A1 (en) 2017-01-19
KR102778576B1 (ko) 2025-03-07
CO2017012988A2 (es) 2018-05-21
TN2017000534A1 (en) 2019-04-12
EP3322726C0 (en) 2025-03-12
CN114478774A (zh) 2022-05-13
PE20181014A1 (es) 2018-06-26
DOP2018000014A (es) 2018-04-15
EP3322726A1 (en) 2018-05-23
HRP20250602T1 (hr) 2025-07-18
AU2016292980B2 (en) 2022-10-06
JP2022003058A (ja) 2022-01-11
CL2020002468A1 (es) 2021-01-29
IL256503B (en) 2022-02-01
NI201800007A (es) 2018-10-18
PL3322726T3 (pl) 2025-06-23
US20230159643A1 (en) 2023-05-25
RU2735639C2 (ru) 2020-11-05
CR20180002A (es) 2018-04-09
BR112018000771A2 (pt) 2018-09-25
US20200190188A1 (en) 2020-06-18
TWI760305B (zh) 2022-04-11
WO2017009327A1 (en) 2017-01-19
PH12018500100A1 (en) 2018-07-30
US20210269524A1 (en) 2021-09-02
US20250277040A1 (en) 2025-09-04
JO3710B1 (ar) 2021-01-31
HK1254356A1 (en) 2019-07-19
IL256503A (en) 2018-02-28
ZA201708613B (en) 2021-03-31
JP2018529635A (ja) 2018-10-11
JP6979397B2 (ja) 2021-12-15
US10889650B2 (en) 2021-01-12
ES3024469T3 (en) 2025-06-04
CL2018000092A1 (es) 2018-07-06
MX2018000506A (es) 2018-05-11
US20180305455A1 (en) 2018-10-25
EA201890038A1 (ru) 2018-06-29
US12331123B2 (en) 2025-06-17
CN107849135A (zh) 2018-03-27
MA42440B1 (fr) 2025-05-30
EP3322726B1 (en) 2025-03-12
KR20180030045A (ko) 2018-03-21
AU2016292980A1 (en) 2018-01-18
ECSP18002725A (es) 2018-03-31
MA42440A (fr) 2018-05-23
HUE071424T2 (hu) 2025-08-28
US20170267761A1 (en) 2017-09-21
GB201512215D0 (en) 2015-08-19
US11548950B2 (en) 2023-01-10
RS66856B1 (sr) 2025-06-30
AR105335A1 (es) 2017-09-27
TW201702273A (zh) 2017-01-16
CN114478775A (zh) 2022-05-13
UA125136C2 (uk) 2022-01-19
RU2018100824A (ru) 2019-08-13
US10428147B2 (en) 2019-10-01
RU2018100824A3 (es) 2020-01-17
US10479835B2 (en) 2019-11-19

Similar Documents

Publication Publication Date Title
SV2018005613A (es) Agentes, usos y metodos para el tratamiento
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
ECSP17018120A (es) Triazolopirazinonas como inhibidores de pde1
CR20170131A (es) Anticuerpos anti-her2 e inmunoconjugados
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
DOP2016000173A (es) Heteroarilos y usos de estos
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
DOP2017000254A (es) Imidazopirazinonas como inhibidores de pde1
BR112019010131A2 (pt) entrega transdérmica de agentes grandes
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
BR112017009000A2 (pt) apilimod para uso no tratamento de melanoma
BR112017008097A2 (pt) método para tratar condições oculares
UY36173A (es) Metodo de tratamiento de enfermedades relacionadas con el factor inducible por hipoxia
ECSP16082599A (es) Quinazolin-thf-aminas halogenadas como inhibidores de pde1
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
ECSP16071574A (es) Hexahidrofuropirroles como inhibidores de pde1
BR112017025264A2 (pt) tratamento de prurido
BR112019006310A2 (pt) método para fabricar digliceróxido de cálcio
PL3582796T3 (pl) Kompozycja do leczenia kaszlu
MX2019002673A (es) Composiciones y metodos para tratar demencia.
IL272023A (en) Methods of treating symptoms of gastroparesis using velusetrag
CR20180110A (es) Libobactina para uso en el tratamiento de la mastitis bovina
EA201991471A1 (ru) Способы введения гепсидина